Introduction
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urban/rural catchment population of approximately 500 000 inhabitants who received universal tax-financed primary and secondary care, free at the point of delivery. Throughout the study period, Aalborg University Hospital was the only referral hospital, and all regional hospitals relied on its Department of Clinical Microbiology for blood culture analyses.
We used high-quality population-based databases with prospectively collected data: the Danish Civil Registration System (CRS), The North Denmark Bacteremia Research Database, 22 the Aarhus University Prescription Database, 23 the regional hospital discharge registry (HDR), 24 and the clinical laboratory information system research database. 25 The CRS contains general personal data for all citizens, updated daily. Unique CRS-numbers, assigned to every Danish resident and used for all healthcare contacts facilitated linkage between databases. The study was approved by the Danish Data Protection Agency (2011-41-5864 ).
Bacteremia and control cohorts
Eligibility criteria for study inclusion were age 15 years, no hospitalization within the previous 30 days, no record of previous bacteremia (since 1981), and study area residence for 1 year.
We assembled three study cohorts. First, we used the Bacteremia Database to identify all adult patients who had a first-time positive blood culture taken on the day of admission to a medical ward during 1992-2010. We defined CAB as the presence of viable bacteria or fungi in the bloodstream, determined by blood cultures performed on the day of admission, among clinically ill patients who were not admitted to the hospital within the previous 30 days. The Bacteremia Database has registered all bacteremia cases in the study area since 1981, with prospective data collection since 1992, and is described in detail elsewhere. 22 It provided information on date of blood culture sampling, number of positive culture bottles, focus of infection, and etiologic agent(s). To assess level of inflammation, we retrieved information on index-date white blood esident and used for all healthcare contacts facilitated linkage between database es s s. T T The he e s stu tu tudy dy dy w was approved by the Danish Data Protection Agency (2011-41-5864 ).
Ba Bact ct cter er erem em mia ia ia a a and d d c c co ontrol cohorts
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We assembled ed d t t thr hr ree ee ee s stu tu tudy dy c c coh oh ohor or orts ts ts. Fi F F rs s st, t, t w w we e e us us used ed ed t t the he he B Bac ac acte te tere re remi mi mia a a Da Da Data ta taba ba base se se d t to o id id iden en enti ti t fy fy fy all adult 5 cell counts (WBCs) and C-reactive protein levels (CRPs) for admissions since 1998 from the laboratory database. We categorized WBC as decreased (<3.5×10^9/L), normal (3.5-10×10^9/L), or increased (>10×10^9/L), and the CRP level as normal (<10 mg/L), increased (10-100 mg/L), or highly increased (>100 mg/L).
Second, to assess the effect of hospitalization with CAB on the risk for AMI/AIS we used the CRS to assemble a matched population control cohort of individuals at risk for their first community-acquired bacteremia as of the admission date of their matched bacteremia patient (the index date). Up to 10 population controls were randomly selected for each bacteremic patient; matched for year of birth, gender, and calendar time.
Third, because acute medical hospitalization itself may increase the risk for subsequent AMI and AIS, we assembled an additional matched hospitalized control cohort of up to five randomly selected acutely admitted medical patients for each CAB patient. Hospitalized controls were patients who were acutely admitted for reasons other than a positive blood culture or a primary diagnosis of cardiovascular disease or rehabilitation (International Classification of Diseases (ICD), ICD-8: 390-458, ICD-10: DI00-99, DZ50). They were matched to CAB patients on sex, year of birth, and calendar year of hospital admission.
Data on cardiovascular outcomes and comorbidity
HDR provided data on all hospitalized events of AMI and AIS and on pre-existing comorbid One primary discharge diagnosis and up to 20 secondary diagnoses are assigned by Third, because acute medical hospitalization itself may increase the risk fo fo for su subs bs bseq eq eque ue uent nt AMI and AIS, we assembled an additional matched hospitalized control cohort of up to five a and nd dom om ml ly ly s s se el ele e ecte te ed d d ac a utely admitted medical pat tie ie ien nt t ts for each CA AB B B pa ati ti tie en ent. Hospitalized controls w wer re re patients wh wh who we wer re a acu cu c te te tely ly ly a adm dm dmit itte ted d d for r r r r reason on ons o ot oth he her r th than an a a p p pos o it it itiv ive e bl bl bloo o ood d cu cu cult lt ltur ure e o or or a a a pr prim im imar ar ary y y di diag ag agno nosi si is of of c c car r rdi diov ova as a cu cu cul l lar ar ar d di is isea ea ease se se or r r re re r ha ha hab bil li lita ta ati ti tio on on ( ( (In In I te te t rn rn rnat at a i io ion na nal l Cl Cl C as as a si si ifi fi fic c cati ti ion n n o of f f : : DI DI DI00 00 00-9 -9 99, 9, 9 D DZ5 Z5 Z50) 0) 0). . Th Th They ey ey w w wer er ere e e ma ma matc tc t he he hed d d to to to C C CAB A patients s 6 physicians at the treating hospital department. The primary diagnosis refers to the condition that prompted patient admission and the main condition responsible for the completed diagnosis and treatment course. The secondary diagnoses refer to conditions that affect the diagnosis and treatment course.
To assess if AMI/AIS did precede CAB in some patients admitted with CAB and a primary diagnosis of AMI/AIS, we examined available electronic hospital files for 21 of the 60 bacteremic patients who had a primary discharge diagnosis of AMI or AIS. In all 21 patients AMI/AIS developed more than 24 hours after admission for suspected infection (n=7) or occurred on the day of admission in patients with ongoing infection (evidenced by microbiological tests performed by the patient's general practitioner, recent antibiotic prescriptions, and/or medical history taking [n=14]). Therefore, we used primary and secondary discharge diagnosis codes to identify episodes of AMI and AIS (Supplemental Table 1 ).
For all three cohorts, we obtained data on pre-existing diseases recorded before the index date, including the 19 disease categories in the Charlson Comorbidity Index, 26 and other conditions described as risk factors for AMI/AIS in the literature. 1 Moreover, we used the Prescription Database to ascertain use of medications before the index date that may affect AMI/AIS risk.
The database has Anatomical Therapeutic Chemical classification (ATC) codes on all reimbursed prescriptions since 1991 (Supplemental Table 1 ).
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Statistics
We followed all study subjects from the index date until first hospitalization for AMI/AIS, death, emigration out of Denmark, or January 1 st 2012, whichever occurred first. Because we expected the risk of AMI and AIS to be highest shortly after onset of infection, we split follow-up into three time periods: 0-30, 31-180, and 181-365 days after the index date. For each time period we microbiological tests performed by the patient's general practitioner, recent anti ib bi biot ot tic ic prescriptions, and/or medical history taking [n=14]). Therefore, we used primary and secondary di isc sc cha ha har rg rge e di di dia ag gno o osi si sis s codes to identify episodes o o of f f AM AMI and AIS (Su Su S pp ple le lem m mental Table 1 ).
F For r al a l three co coho ho h r r rts, s w w we e e ob ob obta ta ain in ined ed da da data ta a o on pr r re---exis st ti ing d d dis isea ea as se es s r r rec co cord rd ded ed e b bef ef for o ore e th th he in in ind de d x x x da a date e e, , n ncl cl clud ud udin in i g g g th th the e e 19 19 di is isea ea ase se c cat a eg eg gor or rie ie ies s s i in in t t the he e C C Ch ha harl rl rlso so on n Co Co omo mo morb rb rbid d dit it ity y In n nde de d x x x, 26 6 6 a and nd nd o o oth ther er er c con n ndi di iti tion on ns s described as r r ris is i k k k fa fa fact ct c or or o s s s fo o or r r AM AM AMI/ I/ I/AI AI AIS S in in in t t the he he l l lit it i er er erat at atur ur ure. e 1 1 1 M M Mor or oreo eo eove ve ver, r w w we e e us us used ed ed t the he e P P Pre re resc sc scri r ption Finally, due to possible residual confounding when comparing hospitalized CAB patients with "healthy" population controls, we performed a sensitivity analysis to estimate how much a potential strong unmeasured confounder might have influenced the observed association (see Supplement).
For Cox models the proportional hazards assumption was checked with log-minus-log plots. Stata 11.2 for Windows (Stata Corp., College Station, TX) was used for all data analyses.
Results
Study subject characteristics
The study included 4389 CAB patients, 43 831 matched population controls, and 21 893 matched hospitalized controls. Median study participant age was 73 years (interquartile range, 61-82 years). CAB patients had a substantially higher burden of pre-existing disease and filled drug prescriptions than background population controls, and a burden similar to other hospitalized patients ( Table 1) . Among CAB patients the 30-day mortality was 15.7%, nearly twice that of hospitalized controls (7.9%), and after one year it was 29.7% (vs. 5.8% for population controls and 23.9% for hospitalized controls) (Supplemental Table 2 ).
potential strong unmeasured confounder might have influenced the observed ass so o ocia ia iati i ion on on ( ( (se se see e e Supplement).
Fo Fo For r r Co Co C x mo mo mode d ls the proportional hazards s s as ass sumption was s ch c ec cke ke ked d with log-minus-log pl lot t ts. s Stata 11. 1 2 2 2 fo o or W Wi W nd nd ndow ow ows s (S (Sta ta ata ta a C C Co or rp., Co Colleg ge e e St t tat at tio ion n n, T T TX X) ) w w was as u u use ed d fo fo for r al all l l da da data ta an na naly y lyse e es.
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Risk for AMI/AIS
Within the first 30 days of follow-up, 3.6% of CAB patients suffered an AMI and/or an AIS (vs. Table 2) .
Risk for AMI/AIS in subgroups
Generally, the finding of an increased risk of AMI and AIS was consistent across subgroups. As expected, CAB patients and controls without previous cardiovascular disease (CVD) had lower absolute risks of AMI and AIS within 0-30 days ( Table 6 ).
Patients who had elevated WBC, increased C-reactive protein levels, or all blood culture bottles positive had high 30-day risk increases for AMI and AIS (Tables 3 and 4 ; also see Supplement).
Supplementary and sensitivity analyses
CAB patients who needed ICU treatment had a 6.0% 30-day risk of AMI/AIS (adj. RR vs. 
Discussion
This study provides evidence that acute admission with CAB is associated with a transient more than 2-fold increased risk of AMI and AIS when compared to other acutely hospitalized patients and a 20-fold increased risk when compared to the background population. Importantly, a more than 60% increased risk for AMI/AIS persists for 1 to 6 months after CAB hospitalization when compared to population controls. Patients with S aureus bacteremia are at particularly increased risk for both early and late AIS. However, all types of CAB increase the short-term risk for cardiovascular events.
To our knowledge, this is the largest cohort study to evaluate the risk of AMI and AIS after microbiologically verified infection. Our 30-day absolute risk estimates for AMI (1.7%) population controls and 50% in CAB, and independently increased the 30-day A AMI MI MI/A /A AIS IS IS r r ris is isk k k by by a factor of 20, the true risk for AMI/AIS following CAB would still be increased 5.73-fold 5 5.0 .0 09-9-9-fo fo fold ld ld f f for or r A AMI MI MI and 6.34-fold for AIS).
Di Di isc sc scus us ussi si s on on n
This study p pro ro ovi vi vide de es s s ev ev vid id den n nce ce ce tha ha hat t t ac ac cut ute e e ad ad admi mi miss ss ssio io ion n n w w wit ith h CA CA CAB B B is is is a a ass s soc oc ocia ia iate te ted d d wi wi w th th th a a a t t tra ra rans n n ient more 12 and AIS (2.1%) are consistent with findings from previous smaller cohort studies. Levine et al.
pooled data from three clinical trials in patients with severe sepsis and septic shock and found that 0.5-1.5% had AMI and 1.0-2.7% had ischemic stroke within 28 days. 7 For patients with respiratory tract infection, we observed absolute risks consistent with previous pneumonia studies. 5, [8] [9] [10] [11] In the largest cohort study conducted to date, Perry et. al evaluated the risk of cardiovascular events among 50 119 patients admitted for pneumonia. 11 Within 30 days following admission, 1.2 % of patients experienced a first-time AMI, and 0.2% a first-time stroke. For endocarditis and meningitis, AMI and AIS risk estimates in our study were particularly high but were less than the 10% reported in previous studies that included hemorrhagic stroke outcomes. 20, 21 Most previous cohort studies on the association between infection and cardiovascular events lacked a comparison group or did not have adequate longterm follow-up. One small cohort study compared 208 patients hospitalized for pneumonia with 395 hospitalized controls and found an 8-fold risk increase for acute coronary syndrome within 15 days, 9 higher than our 2.2-fold increased RR within 30 days.
Case-only study designs have been used to examine short-term risk of acute coronary syndrome and stroke after hospitalization for infection. 6, 9, 12 Patients were included in these studies if they had both a transient exposure (infection) and an acute outcome of interest (AMI or stroke) during an observation period. The outcome-risk was compared for different time periods with each patient serving as his/her own control. In 32 patients the risk of acute coronary syndrome increased 50-fold within a 15-day period after hospitalization for pneumonia. 9 Likewise, in 42 patients the risk of AMI was 35-fold higher within 2 days after recognition of S aureus bacteremia 6 , and in 669 patients the risk of stroke was 8-fold higher within 2 weeks after infection. 12 These estimates are comparable to our 20-fold increased RR vs. population controls.
hemorrhagic stroke outcomes. 20, 21 Most previous cohort studies on the associatio on n n be be b tw tw wee ee een n n nfection and cardiovascular events lacked a comparison group or did not have adequate longe erm rm m f f fol ol ollo lo low-w-w u u up. On On One e small cohort study compar red ed ed 2 2 208 patients ho ho osp s it tal al aliz iz ized for pneumonia with Several mechanisms explain why bacterial infections can trigger cardiovascular events.
In theory, any severe infection that causes hypotension may disturb the balance between myocardial or cerebral metabolic supply and demand and trigger an ischemic event. 15 Toxins from Gram-negative and Gram-positive bacteria can impair myocardial function 16 and damage the endothelium. 17 Furthermore, bacteria can provoke inflammation-induced activation of the coagulatory system and directly activate platelets 18 , which may lead to thrombosis. Moreover, septic embolism may be important. The markedly increased risk only within the first 30 days after bacteremia supports a pathogenic link between acute inflammation associated with bacterial infection and vascular events. In a previous study, Grau et al. found that an increased neutrophil count heralds a short period at increased risk for recurrent ischemic events. 27 Moreover, previous studies have shown that more severe in-hospital infection is associated with higher risk increases for AMI and AIS than less severe infection treated in primary care. 2, 4, 13, 14 We found that high levels of inflammatory markers such as CRP and WBC, and high bacteremia severity as reflected by multiple culture bottles being positive or need for ICU stay predicted high risk increases for AMI/AIS. However, due to limited precision of estimates we cannot conclude that more severe n theory, any severe infection that causes hypotension may disturb the balance b be betw tw wee ee en n myocardial or cerebral metabolic supply and demand and tr a igger an ischemic event. 15 Toxins fr rom om m G G Gra ram-m-m-ne nega a ati ti tiv ve ve and Gram-positive bacteria a a ca can n impair myoca ca c rdia ia al l l f fu function 16 and damage h h he en e dotheliu um. m. . 17 7 F Fu ur rth h her er rmo mo mor re re, , b ba bac ct cte er ria a a can n n p p prov vo vok ke n in infl fla am mma mat tio on on-i -i ind n n u uc uced ed d a act ctiv iv vat at tio io ion n n of of of t th he h co oag ag agul ul ulat at a or ory y y s sy syst stem em em a an nd nd d di ire r ct ct c ly ly y a a act ct cti iv iva at ate e pl pl pla at atel el let et e s s 1 18 , , w wh whic ic ch h h ma ma ay y y l l lead ad ad t to o o th h hro romb mb mbos os o is is is. . Mo Mo ore e eov ove e er, , eptic embol lis is sm m m ma ma may y y be be be imp mp mpor o o ta ta tant nt n . . Th Th The e e ma ma mark rk rked ed edly ly ly in in incr cr c ea ea ase se sed d d ri ri isk sk sk o onl nl nly y y wi wi with th thin in in t the he he f f fir ir rst st st 3 30 days 14 inflammation or more severe disease confers a greater risk for AMI/AIS than lower levels of inflammation and severity.
Finally, our findings suggest that patients with S aureus infection may have a particularly high propensity for thrombosis.
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Strengths of the present study included large sample size, population-based design, and complete follow-up of all study subjects. We had access to high quality microbiological data and captured all diagnosed cases of hospitalized CAB over a 20-year period in the study population. 22 Our data on AMI/AIS had high validity. [29] [30] [31] Because all data was prospectively collected in independent databases, recall and investigator bias was negligible.
Our study had some limitations. Heart failure and stroke are known risk factors for infection, with risk of reverse causation bias. To increase the likelihood that infection preceded AMI/AIS we limited our study to patients who had a positive blood culture on the day of admission. Furthermore, our medical record review did not reveal reverse causation bias in any patient, and CAB remained associated with AMI/AIS in various sensitivity analyses.
CAB patients were already receiving medical attention and therefore potentially more likely to be diagnosed with AMI/AIS. However, AMI and AIS are serious acute conditions that usually lead to hospital contact. Out-of-hospital deaths from AMI/AIS may have decreased risk estimates for population controls. On the other hand, severe infection may lead to death before AMI/AIS is diagnosed in hospitalized patients. A third possible limitation is that troponin spill during severe infection may have falsely inflated AMI risk estimates. 32 However, the AMI risk was similar before and after the introduction of troponin assays in clinical practice. Because death was a competing risk in this study, the usual 1-to-1 correspondence between risk and rate was lost. 33 Therefore, hazard ratios of AMI and AIS during 31-180 and 181-365 days should be Our study had some limitations. Heart failure and stroke are known risk f f fa a acto to t r rs s f f for or or nfection, with risk of reverse causation bias. To increase the likelihood that infection preceded AM AM MI/ I/ I/AI AI AIS S S we w w lim m mit it ited ed our study to patients who h h had ad a a positive bloo oo od cu cu ult lt ltu u ure on the day of ad dm mi mission. Fur urth th ther r rmo more re, , ou ou o r r r me m medi di ica ca cal l r r rec c cord d d re e eview ew w did d d n n not ot t re ev eve ea al l rev eve e ers se e c c cau au ausa sati ti ion on on b b bia ia i s s i in in a a an ny ny pa pati ti tien en nt, t, t, a and nd d C C CAB AB B r r rem em mai aine ne n d d a as asso so oci ci ciat at ated ed w w wit it ith h h AM AM MI/ I/ /AI AIS in in n v v va ar ario o ous us u sen en ensi sit ti tiv vi ity ty a a ana na naly ly yse se ses s s.
CAB B pa pa pati ti t en en ents ts t w w wer e e e e al al alre r r ad ad ady y y re re rece e eiv iv ivin in ing g g me me medi di d ca ca cal l l att tt tten en enti ti t on on on a a and nd n t t the he here re ref f for or ore e e po po pote te tent nt ntia ia all l y more f f f f f f 15 interpreted with some caution. Although we were able to adjust for a wide range of confounders, residual and unmeasured confounding may have occurred. For example, we lacked information on smoking status and relied on proxy variables for smoking (e.g., chronic pulmonary disease).
However, to nullify our findings, an unmeasured confounder would have to be extremely strong.
The fact that there was no adjusted risk increase for AMI/AIS in CAB patients versus both control cohorts after more than 180 days argues against substantial unmeasured confounding factors.
In conclusion, patients admitted with CAB had a transient increased risk of AMI and AIS. The risk of AMI/AIS was greatest during the first 30 days after the infection although a modestly elevated risk in particular for AIS was observed for 6 months post-infection. There is a need for a better understanding of the mechanisms including metabolic supply/demand mismatch and embolic events that may increase the risk for cardiovascular events following severe infection. Improving our understanding of these mechanisms through future experimental and observational studies may lead to more targeted prevention and treatment strategies. Research Foundation. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. 98 98 982) 2) 2) 2 2 Previous CVD defined as any previous diagnosis of AMI, heart failure, atrial fibrillation or stroke.
‡ Blood culture bottle data from 1996-2010 and WBC and CRP-data from 1998-2010. Blood culture data on number of bottles was missing for 0.1% of patients (categorized as "Some positive"), WBC data for 0.8% (categorized as normal, i.e. 3.5-10×10^9/L), and CRP data for 1.0% (categorized as normal, i.e. <10 mg/L). CVD VD V , card rd dio io i va va v sc scul u ar a a disea e e e se s . CN , S S cen en e tr tral a a n ner e vo v us s s syste te t m. m W WBC B , wh w w t it i e bl u unt nt nt. CR CR CRP, , C C-re eac acti ti tive ve v p pro o rote t n in i . ve ve r ris is isk k k s esti ti tima ma mate te tes s s ar are e co co ont n n o roll ll lled ed ed f f for ag ag age, e, e gende de der, r, cal len en enda dar-r-i ti time m m , an an nd d d an ny y y co co como m m b rb rbid id id t t ity y y (e (exc xc cep ep ept t wh wh wher re e st s ra ati ti tifi fied ed ed by y co co c mo morb rb rb d id idit it ity) y) y). . † † Pr Pr P ev ev vio io ious C C CVD VD VD d f ef efin in ined evio ous us d dia iagnos osis is of AM AMI, h hea eart rt f fai a lure, at a rial al f fib ib i rill llat atio i n or str trok oke. e. Abbreviations: CAB, community-acquired bacteremia. CI, confidence interval. CVD, cardiovascular disease. CNS, central nervous system. WBC, white blood cell count. CRP, C-reactive protein.
*
Relative risk estimates are controlled for age, gender, calendar-time, and any comorbidity (except where stratified by comorbidity). † Previous CVD defined as any previous diagnosis of AMI, heart failure, atrial fibrillation or stroke. ‡ Blood culture bottle data from 1996-2010 and WBC and CRP-data from 1998-2010. Blood culture data on number of bottles was missing for 0.1% of patients (categorized as "Some positive"), WBC data for 0.8% (categorized as normal, i.e. 3.5-10×10^9/L), and CRP data for 1.0% (categorized as normal, i.e. <10 mg/L).
